Although the study sample was too small (n = 72) to draw any solid conclusions, the results provide evidence of the potential benefit of early intervention with the drug ivermectin for the treatment of adult patients diagnosed with mild COVID-19. First, early intervention promoted faster viral clearance during disease onset, which might have prevented significant immune system involvement and hastened the recovery. Secondly, early intervention reduced the viral load faster, thus may help block disease transmission in the general population. A larger randomized controlled clinical trial of ivermectin treatment appears to be warranted to validate these important findings.